PPQJX
Price
$7.81
Change
-$0.04 (-0.51%)
Updated
Sep 20 closing price
RPTIX
Price
$109.40
Change
-$0.77 (-0.70%)
Updated
Sep 20 closing price
Ad is loading...

PPQJX vs RPTIX

Header iconPPQJX vs RPTIX Comparison
Open Charts PPQJX vs RPTIXBanner chart's image
Principal MidCap Growth III J
Price$7.81
Change-$0.04 (-0.51%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Mid-Cap Growth I
Price$109.40
Change-$0.77 (-0.70%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
PPQJX vs RPTIX Comparison Chart
Loading...
VS
PPQJX vs. RPTIX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PPQJX is a StrongBuy and RPTIX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 31.4B vs. PPQJX (447M). RPTIX pays higher dividends than PPQJX: RPTIX (0.18) vs PPQJX (0.00). PPQJX was incepted earlier than RPTIX: PPQJX (24 years) vs RPTIX (9 years). PPQJX is a more actively managed with annual turnover of: 49.40 vs. RPTIX (21.70). PPQJX has a lower initial minimum investment than RPTIX: PPQJX (1000) vs RPTIX (500000). RPTIX annual gain was more profitable for investors over the last year : 14.81 vs. PPQJX (6.11). RPTIX return over 5 years is better than : 15.09 vs. PPQJX (-18.65).
PPQJXRPTIXPPQJX / RPTIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence24 years9 years-
Gain YTD3.5819.12739%
Front LoadN/AN/A-
Min. Initial Investment10005000000%
Min. Initial Investment IRAN/AN/A-
Net Assets447M31.4B1%
Annual Yield % from dividends0.000.18-
Returns for 1 year6.1114.8141%
Returns for 3 years-40.61-13.57299%
Returns for 5 years-18.6515.09-124%
Returns for 10 years-28.94N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLH246.88-0.54
-0.22%
Clean Harbors
TOI0.29N/A
-0.58%
Oncology Institute (The)
CINT6.59-0.04
-0.60%
CI&T
CSTM16.22-0.54
-3.22%
Constellium SE
KTTA4.43-0.37
-7.71%
Pasithea Therapeutics Corp